CENTESSA PHARMACEUTICALS-ADR (CNTA) Fundamental Analysis & Valuation

NASDAQ:CNTA • US1523091007

Current stock price

39.57 USD
+0.15 (+0.38%)
At close:
39.57 USD
0 (0%)
After Hours:

This CNTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CNTA Profitability Analysis

1.1 Basic Checks

  • CNTA had negative earnings in the past year.
  • CNTA had a negative operating cash flow in the past year.
  • In the past 5 years CNTA always reported negative net income.
  • CNTA had a negative operating cash flow in each of the past 5 years.
CNTA Yearly Net Income VS EBIT VS OCF VS FCFCNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • CNTA has a Return On Assets of -28.73%. This is in the better half of the industry: CNTA outperforms 66.99% of its industry peers.
  • CNTA's Return On Equity of -37.49% is fine compared to the rest of the industry. CNTA outperforms 68.74% of its industry peers.
Industry RankSector Rank
ROA -28.73%
ROE -37.49%
ROIC N/A
ROA(3y)-37.18%
ROA(5y)-44.15%
ROE(3y)-53.39%
ROE(5y)-60.4%
ROIC(3y)N/A
ROIC(5y)N/A
CNTA Yearly ROA, ROE, ROICCNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CNTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTA Yearly Profit, Operating, Gross MarginsCNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CNTA Health Analysis

2.1 Basic Checks

  • CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CNTA has a better debt/assets ratio than last year.
CNTA Yearly Shares OutstandingCNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M
CNTA Yearly Total Debt VS Total AssetsCNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 19.95 indicates that CNTA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CNTA (19.95) is better than 87.96% of its industry peers.
  • A Debt/Equity ratio of 0.21 indicates that CNTA is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.21, CNTA is not doing good in the industry: 67.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 19.95
ROIC/WACCN/A
WACC9.28%
CNTA Yearly LT Debt VS Equity VS FCFCNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 8.57 indicates that CNTA has no problem at all paying its short term obligations.
  • CNTA has a Current ratio of 8.57. This is in the better half of the industry: CNTA outperforms 74.17% of its industry peers.
  • A Quick Ratio of 8.57 indicates that CNTA has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 8.57, CNTA is doing good in the industry, outperforming 74.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.57
Quick Ratio 8.57
CNTA Yearly Current Assets VS Current LiabilitesCNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CNTA Growth Analysis

3.1 Past

  • CNTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.03%, which is quite good.
EPS 1Y (TTM)15.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 27.19% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 125.62% on average over the next years. This is a very strong growth
EPS Next Y-19.61%
EPS Next 2Y-12.74%
EPS Next 3Y-0.79%
EPS Next 5Y27.19%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y117.42%
Revenue Next 5Y125.62%

3.3 Evolution

CNTA Yearly Revenue VS EstimatesCNTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
CNTA Yearly EPS VS EstimatesCNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CNTA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNTA. In the last year negative earnings were reported.
  • Also next year CNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTA Price Earnings VS Forward Price EarningsCNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTA Per share dataCNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.74%
EPS Next 3Y-0.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CNTA Dividend Analysis

5.1 Amount

  • CNTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CNTA Fundamentals: All Metrics, Ratios and Statistics

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (5/1/2026, 8:18:43 PM)

After market: 39.57 0 (0%)

39.57

+0.15 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-31
Earnings (Next)05-12
Inst Owners87.28%
Inst Owner Change0.48%
Ins Owners0.52%
Ins Owner Change1.5%
Market Cap6.12B
Revenue(TTM)15.00M
Net Income(TTM)-197.53M
Analysts81.05
Price Target44.88 (13.42%)
Short Float %2.42%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.52%
Min EPS beat(2)-23.57%
Max EPS beat(2)-3.48%
EPS beat(4)1
Avg EPS beat(4)3.08%
Min EPS beat(4)-23.57%
Max EPS beat(4)47.36%
EPS beat(8)3
Avg EPS beat(8)1.01%
EPS beat(12)6
Avg EPS beat(12)6.41%
EPS beat(16)9
Avg EPS beat(16)5.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.99%
PT rev (3m)11.72%
EPS NQ rev (1m)-4.48%
EPS NQ rev (3m)-0.95%
EPS NY rev (1m)-4.98%
EPS NY rev (3m)-4.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 408
P/FCF N/A
P/OCF N/A
P/B 11.62
P/tB 11.62
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS0.1
BVpS3.41
TBVpS3.41
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -28.73%
ROE -37.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.18%
ROA(5y)-44.15%
ROE(3y)-53.39%
ROE(5y)-60.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.28%
Cap/Sales 2.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.57
Quick Ratio 8.57
Altman-Z 19.95
F-Score5
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)21.59%
Cap/Depr(5y)315%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.24%
EPS Next Y-19.61%
EPS Next 2Y-12.74%
EPS Next 3Y-0.79%
EPS Next 5Y27.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y117.42%
Revenue Next 5Y125.62%
EBIT growth 1Y-3.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.84%
EBIT Next 3Y-16.77%
EBIT Next 5YN/A
FCF growth 1Y-36.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.44%
OCF growth 3YN/A
OCF growth 5YN/A

CENTESSA PHARMACEUTICALS-ADR / CNTA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CNTA.


What is the valuation status for CNTA stock?

ChartMill assigns a valuation rating of 0 / 10 to CENTESSA PHARMACEUTICALS-ADR (CNTA). This can be considered as Overvalued.


What is the profitability of CNTA stock?

CENTESSA PHARMACEUTICALS-ADR (CNTA) has a profitability rating of 1 / 10.


What is the expected EPS growth for CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?

The Earnings per Share (EPS) of CENTESSA PHARMACEUTICALS-ADR (CNTA) is expected to decline by -19.61% in the next year.